HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Clinical trials for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Cancer's fuel line in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, colorectal, or lung cancer) that have not responded to standard treatments. The drug works by blocking a key cancer growth signal (PI3Kα:RAS). The main goals are to find a safe …
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) • Aim: Disease control
Last updated May 17, 2026 03:55 UTC
-
New drug combo aims to slow advanced breast cancer
Disease control Recruiting nowThis study tests two different doses of the drug dalpiciclib combined with letrozole in 120 women with a specific type of advanced breast cancer (HR-positive, HER2-negative). The goal is to see how long the cancer stays under control. Participants are randomly assigned to one of …
Matched conditions: HR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: wanghaibo • Aim: Disease control
Last updated May 17, 2026 03:53 UTC